A Phase 3 interventional study of Ferric maltol and Placebo in Renal Insufficiency, Chronic and Iron-Deficiency Anemia, sponsored by Shield Therapeutics. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 248th largest by enrollment of the 819 interventional ones that give a count, is one of 46 that started in 2016, is one of 147 in phase 3, and was the 452nd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 46 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 696 that completed or were terminated, 344 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Iron deficiency anemia defined by the following criteria assessed via screening laboratory results:
Exclusion Criteria:
Anemia due to any cause other than iron deficiency, including, but not limited to:
Administration with any of the following prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30mg capsules BID
Drug: Ferric maltol
Matching placebo capsules BID
Other: Placebo
Also known as: Feraccru
Change in Hb Concentration From Baseline to Week 16
Change in hemoglobin concentration from baseline to Week 16.
Time frame: 16 weeks
Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16
Number of subjects that achieve an increase in Hemoglobin concentration of ≥1 g/dL at Week 16
Time frame: 16 weeks
Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16
Number of subjects that achieve a Hemoglobin concentration of ≥11 g/dL at week 16
Time frame: 16 weeks
Change in Hb Concentration From Baseline to Week 8
Change in Hemoglobin concentration from baseline to Week 8
Time frame: 8 weeks
Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16
Number of subjects that achieve an increase in Hemoglobin concentration of ≥2 g/dL at Week 16
Time frame: 16 weeks
Changes in Ferritin From Baseline to Week 16
Changes in iron parameter - ferritin - from baseline to week 16
Time frame: baseline to week 16
Number of Participants With (TEAEs)
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Week 16
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the double blind phase
Time frame: Week 16
Changes in TSAT From Baseline to Week 16
Changes in iron parameters - TSAT - from baseline to week 16
Time frame: baseline to week 16
Changes in Iron Parameter From Baseline to Week 16
Changes in iron parameters - serum iron - from baseline to week 16
Time frame: from baseline to week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) during the open label phase
Time frame: Week 52
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the open label phase
Time frame: Week 52
| Milestone | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Started | 111 | 56 |
| Completed | 90 | 39 |
| Not completed | 21 | 17 |
| Milestone | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Started | 86 | 39 |
| Completed | 67 | 25 |
| Not completed | 19 | 14 |
Change in hemoglobin concentration from baseline to Week 16.
| g/dl | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 16 | 0.50 ± 0.122 | -0.02 ± 0.165 |
Number of subjects that achieve an increase in Hemoglobin concentration of ≥1 g/dL at Week 16
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Subjects That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 16 | 22 | 5 |
Number of subjects that achieve a Hemoglobin concentration of ≥11 g/dL at week 16
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Subjects That Achieve a Hb Concentration of ≥11 g/dL at Week 16 | 30 | 7 |
Change in Hemoglobin concentration from baseline to Week 8
| g/dl | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Change in Hb Concentration From Baseline to Week 8 | 0.53 ± 0.901 | 0.00 ± 0.909 |
Number of subjects that achieve an increase in Hemoglobin concentration of ≥2 g/dL at Week 16
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Subjects That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 16 | 7 | 0 |
Changes in iron parameter - ferritin - from baseline to week 16
| ug/l | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Changes in Ferritin From Baseline to Week 16 | 33.13 ± 6.166 | -5.90 ± 9.137 |
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Participants With (TEAEs) | 75 | 42 |
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the double blind phase
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) | 23 | 12 |
Changes in iron parameters - TSAT - from baseline to week 16
| TSAT (%) | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Changes in TSAT From Baseline to Week 16 | 4.32 ± 0.719 | -0.15 ± 1.060 |
Changes in iron parameters - serum iron - from baseline to week 16
| umol/l | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Changes in Iron Parameter From Baseline to Week 16 | 1.87 ± 0.397 | 0.01 ± 0.586 |
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) during the open label phase
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 76 | 35 |
Number of Participants with Treatment-Emergent Serious Adverse Events (TESAEs) during the open label phase
| Participants | Oral Ferric Maltol | Oral Placebo |
|---|---|---|
| Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) | 27 | 9 |
Collected over 16 week double blind phase. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Ferric Maltol DB | 75/111 (67.6%) | 23/111 (20.7%) | 75/111 (67.6%) |
| Oral Placebo DB | 42/56 (75%) | 12/56 (21.4%) | 42/56 (75%) |
| Oral Ferric Maltol OL | 76/86 (88.4%) | 27/86 (31.4%) | 76/86 (88.4%) |
| Oral Placebo OL | 35/39 (89.7%) | 9/39 (23.1%) | 35/39 (89.7%) |
| Event | Oral Ferric Maltol DB | Oral Placebo DB | Oral Ferric Maltol OL | Oral Placebo OL |
|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/111 | 0/56 | 1/86 | 2/39 |
| Acute kidney injuryRenal and urinary disorders | 1/111 | 1/56 | 1/86 | 2/39 |
| AnemiaBlood and lymphatic system disorders | 0/111 | 2/56 | 0/86 | 0/39 |
| Angina pectorisCardiac disorders | 0/111 | 1/56 | 0/86 | 1/39 |
| HyperglycemiaMetabolism and nutrition disorders | 1/111 | 0/56 | 0/86 | 1/39 |
| HyperkalemiaMetabolism and nutrition disorders | 0/111 | 1/56 | 1/86 | 1/39 |
| Hypertensive emergencyVascular disorders | 1/111 | 1/56 | 1/86 | 1/39 |
| Mental status changesPsychiatric disorders | 0/111 | 1/56 | 0/86 | 1/39 |
| CoagulopathyBlood and lymphatic system disorders | 0/111 | 0/56 | 1/86 | 1/39 |
| Acute myocardial infarctionCardiac disorders | 0/111 | 0/56 | 1/86 | 1/39 |
| Event | Oral Ferric Maltol DB | Oral Placebo DB | Oral Ferric Maltol OL | Oral Placebo OL |
|---|---|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 45/111 | 17/56 | 48/86 | 18/39 |
| Infections and infestationsInfections and infestations | 17/111 | 13/56 | 39/86 | 19/39 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 21/111 | 13/56 | 25/86 | 13/39 |
| Respiratory, thoracic, and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 0/111 | 0/56 | 19/86 | 7/39 |
| Injury, poisoning, and procedural complicationsInjury, poisoning and procedural complications | 0/111 | 0/56 | 17/86 | 4/39 |
| General disorders and administration site conditionsGeneral disorders | 0/111 | 0/56 | 16/86 | 5/39 |
| Vascular disordersVascular disorders | 0/111 | 0/56 | 16/86 | 5/39 |
| ConstipationGastrointestinal disorders | 9/111 | 2/56 | 14/86 | 5/39 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 5/111 | 9/56 | 0/86 | 0/39 |
| HyperkalemiaMetabolism and nutrition disorders | 4/111 | 7/56 | 5/86 | 6/39 |
| Age, Categorical(Participants) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 19 | 53 |
| >=65 years | 77 | 37 | 114 |
| Age, Continuous(years) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| Mean | 68.5 ± 12.43 | 65.2 ± 12.79 | 67.4 ± 12.61 |
| Sex: Female, Male(Participants) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| Female | 78 | 39 | 117 |
| Male | 33 | 17 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 14 | 40 |
| Not Hispanic or Latino | 84 | 42 | 126 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 23 | 12 | 35 |
| White | 81 | 42 | 123 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 2 | 6 |
| Region of Enrollment(participants) | Oral Ferric Maltol | Oral Placebo | Total |
|---|---|---|---|
| United States | 111 | 56 | 167 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Jan 2018, 13 months.
Results were first posted in May 2020, 2 years 3 months after primary completion.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 13 months is below that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Renal Insufficiency, Chronic →
Shield Therapeutics